Vascepa, also known as icosapent ethyl, is a prescription medication approved for reducing triglyceride levels in the blood [1]. Research has shown that Vascepa offers several benefits over other medications for treating high triglycerides.
One key benefit of Vascepa is its ability to reduce the risk of cardiovascular events, such as heart attacks and strokes, in patients with high triglyceride levels [2]. In fact, a large clinical trial, known as the STRENGTH study, found that Vascepa significantly reduced the risk of major adverse cardiovascular events when used in combination with statins [3].
Another benefit of Vascepa is its favorable safety profile compared to some other medications used to treat high triglycerides. Vascepa is generally well-tolerated and has a lower risk of gastrointestinal side effects, such as nausea and diarrhea, compared to some other medications in its class [4].
Furthermore, Vascepa has been shown to have additional cardiovascular benefits beyond just lowering triglycerides. It has been found to improve blood lipid profiles, including increasing levels of high-density lipoprotein (HDL) or "good" cholesterol, and reducing levels of low-density lipoprotein (LDL) or "bad" cholesterol [5].
In comparison to other medications, such as fibrates and niacin, Vascepa has been shown to be more effective at reducing triglyceride levels and improving cardiovascular risk factors [6]. Additionally, Vascepa has a more predictable dosing regimen compared to niacin, which can have variable effects on lipid levels [7].
According to DrugPatentWatch.com, Vascepa is covered by a patent that is set to expire in 2038 [8]. As a result, generic versions of the medication may become available, making it more accessible to patients. However, it's worth noting that the quality of generic medications can vary, and patients should always consult with their healthcare provider before switching to a generic version of their medication.
In summary, Vascepa offers several benefits over other medications for treating high triglycerides, including a favorable safety profile, improved cardiovascular outcomes, and additional cardiovascular benefits beyond just lowering triglycerides.
Sources:
[1] https://en.wikipedia.org/wiki/Vascepa
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291513/
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289119/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185143/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291513/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169118/
[8] https://www.drugpatentwatch.com/patent/US10541959